2-phenylethanol Odor Exposure for Epilepsy Apnea Prevention
2-phenylethanol rose scent
Sudden Unexpected Death in Epilepsy+5
+ Brain Diseases
+ Central Nervous System Diseases
Prevention Study
Summary
Study start date: July 1, 2025
Actual date on which the first participant was enrolled.This study explores the potential of using rose scent as a way to prevent sudden unexpected death in epilepsy (SUDEP), which affects about 1 in 1000 epilepsy patients each year. SUDEP often occurs due to breathing issues during seizures, but the exact cause is still unclear, making it hard to treat. By studying adult epilepsy patients in a hospital setting, researchers aim to see if exposure to the scent of roses can improve respiratory function during seizures, possibly reducing the risk of SUDEP. This study hopes to provide a better understanding of how scents might help manage epilepsy and save lives. Participants in the study will be adults admitted for epilepsy monitoring, where they will wear a non-invasive respiratory belt and undergo routine EEG monitoring. Initially, they will be tested for their ability to identify common scents and their mood will be assessed. Over the course of the study, participants will spend 24 hours in a room with no scent exposure and another 24 hours with rose scent diffused in the room. The researchers will evaluate changes in seizure activity and breathing patterns by comparing data from these two periods. The study carries minimal risks, with rose scent exposure being generally safe and potentially having calming effects.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.40 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Prevention Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: * Adult epilepsy patients over the age of 18 * Admission to the inpatient epilepsy monitoring unit (EMU) at Vanderbilt University Medical Center (VUMC) * Undergoing observational EEG monitoring without treatment involving seizure medication changes or other interventions for at least 48 hours Exclusion Criteria: * Patients under the age of 18 * Patients receiving EEG monitoring without interventions from baseline for less than 48 hours * Patients who are not receiving EEG monitoring as a part of their inpatient admission.
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalStudy Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location